Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment.

González-García, Andrés; García-Sánchez, Isabel; Lopes, Vanessa; Moreno-Arrones, Oscar Muñoz; Tortosa-Cabañas, Marina; Elías-Sáenz, Isabel; Hernández-Rodríguez, José

Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment.

González-García, Andrés; García-Sánchez, Isabel; Lopes, Vanessa; Moreno-Arrones, Oscar Muñoz; Tortosa-Cabañas, Marina; Elías-Sáenz, Isabel; Hernández-Rodríguez, José.

González-García A; Department of Internal Medicine.
García-Sánchez I; Department of Internal Medicine, Autoimmune and Rare Diseases Unit, Hospital Universitario Ramón y Cajal, Universidad de Alcalá de Henares, IRYCIS, Madrid.
Lopes V; Department of Internal Medicine.
Moreno-Arrones OM; Department of Internal Medicine.
Tortosa-Cabañas M; Department of Internal Medicine.
Elías-Sáenz I; Department of Internal Medicine.
Hernández-Rodríguez J; Department of Internal Medicine.

Rheumatology (Oxford) ; 59(8): 2171-2173, 2020 08 01.

Article in English | MEDLINE | ID: covidwho-610246

Subject(s)

Coronavirus Infections/drug therapy; Interleukin 1 Receptor Antagonist Protein/therapeutic use; Pneumonia, Viral/drug therapy; Betacoronavirus; COVID-19; Humans; Injections, Subcutaneous; Interleukin 1 Receptor Antagonist Protein/administration & dosage; Male; Middle Aged; Pandemics; SARS-CoV-2; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Interleukin 1 Receptor Antagonist Protein Type of study: Case report / Prognostic study Limits: Humans / Male / Middle aged Language: English Journal: Rheumatology (Oxford) Journal subject: Rheumatology Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google